Animal models for studying the action of topoisomerase I targeted drugs

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1400, Issue 1-3, 1998, Pages 301-319

  Thompson, Joyce ^a   Stewart, Clinton F ^a   Houghton, Peter J ^a  

^a St Jude Children's Research Institute   (United States)

Author keywords

Combination chemotherapy; Human tumor; Interspecies difference; Rodent tumor; Schedule dependence; Toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; AZASERINE; BUSULFAN; COLCHICINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; IRINOTECAN; MELPHALAN; MITOBRONITOL; MITOLACTOL; RUBITECAN; SARCOLYSIN; THIOTEPA; TOPOTECAN; TRETAMINE; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; REVIEW; SPECIES DIFFERENTIATION; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL DIVISION; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; RODENTIA; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032190443     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(98)00143-2     Document Type: Review

References (55)

1. Trask D.K., Muller M.T. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. USA. 85:1988;1417-1421.
2. J.F. Holland, E. Frei III, R.C. Bast Jr., D.W. Kufe, D.L. Morton, R.R. Weichselbaum (Eds.), Cancer Medicine, 4th edn., 1997.
3. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., Silber R., Pomesil M. DNA topoisomerase 1-targeted chemotherapy of human colon cancer xenografts. Science. 246:1989;1046-1048.
4. DeWys W.D., Humphreys S.R., Goldin A. Studies on the therapeutic effectiveness of drugs with tumor weight and survival time indices of Walker 256 carcinosarcoma. Cancer Chemother. Rep. 52:(2):1968;229-242.
5. Gallo R.C., Whang-Peng J., Adamson R.H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 46:1971;789-795.
6. Gottlieb J.A., Guarino A.M., Call J.B., Oliverio V.T., Block J.B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep. 54:1970;461-470.
7. Moertel C.G., Schutt A.J., Reitemeier R.J., Hahn R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56:1972;95-101.
8. Kingsbury W.D., Boehm J.C., Jakas D.R., Holden K.G., Hecht S.M., Gallagher G., Caranfa M.J., McCabe F.L., Faucette L.F., Johnson R.K., Hertzberg R.P. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem. 4:1990;98-107.
9. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:1985;14873-14878.
10. Chen A.Y., Liu L.F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 34:1994;191-218.
11. Nitiss J., Wang J.C. DNA topoisomerase-targeted drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA. 85:1988;7501-7505.
12. L.F. Liu, Topoisomerase-I targeted drugs. Mechanism of inhibition and cytotoxicity, in: T. Taguchi, J.C. Wang (Eds.), Vth World Conference on Clinical Pharmacology and Therapeutics. Highlights of a Satellite Symposium: Approaches to Cancer Treatment by Topoisomerase-I Inhibitors, Biomedis, Tokyo, 1992, pp. 6-9.
13. McCabe F.L., Johnson R.K. Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest. 12:1994;308-313.
14. Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., Miyasaka T., Mutai M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res. 47:1987;5944-5947.
15. Matsuzaki T., Yokokura T., Mutai M., Tsuruo T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol. 21:1988;308-312.
16. Bissery M.C., Vrignaud P., Lavelle F., Chabot G.G. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11). Anti-Cancer Drugs. 7:1996;437-460.
17. Kawato Y., Furuta T., Aonuma M., Yasuoka M., Yokokura T., Matsumoto K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol. 28:1991;192-198.
18. Pantazis P., Hinz H.R., Mendoza J.T., Kozielski A.S., Williams L.J., Stehlin J.S. Jr., Giovanella B.C. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res. 52:1992;3980-3987.
19. Houghton P.J., Cheshire P.J., Myers L., Stewart C.F., Synold T.W., Houghton J.A. Evaluation of 9-dimethylaminomethyl-l0-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol. 31:1992;229-239.
20. Pentazis P., Kozielski A.J., Vardeman D.M., Petry E.R., Giovanella B.C. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol. Res. 5:1993;273-281.
21. Houghton P.J., Cheshire P.J., Hallman J.C., Bissery M.C., Mathieu-Boue A., Houghton J.A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res. 53:1993;2823-2829.
22. Komuro H., Li P., Tsuchida Y., Yokomori K., Nakajima K., Aoyama T., Kaneko M., Kaneda N. Effects of CPT11 (a unique DNA topoisomerase 1 inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med. Pediatr. Oncol. 23:1994;487-492.
23. Houghton P.J., Cheshire P.J., Hallman J.D., Lutz L., Friedman H.S., Danks M.K., Houghton J.A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36:1995;393-403.
24. Emerson D.L., Besterman J.M., Brown H.R., Evans M.G., Leitner P.P., Luzzio M.J., Shaffer J.E., Sternbach D.D., Uehling D., Vuong A. In vivo antitumor activity of two seven-substituted water soluble camptothecin analogues. Cancer Res. 55:1995;603-609.
25. Vassal G., Terrier-Lacombe M.J., Bissery M.C., Venuat A.M., Gyergyay F., Benard J., Morizet J., Boland I., Ardouin P., Bressac-de-Paillerets B., Gouyette A. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br. J. Cancer. 74:1996;537-545.
26. Thompson J., Zamboni W.C., Cheshire P.J., Lutz L., Luo X., Li Y., Houghton J.A., Houghton P.J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res. 3:1997;423-431.
27. Thompson J., Zamboni W.C., Cheshire P.J., Richmond L., Luo X., Houghton J.A., Stewart C.F., Houghton P.J. Efficacy of oral administration of irinotecan against neuroblastoma xenografts. Anti-Cancer Drugs. 8:1997;313-322.
28. Hare C.B., Elion G.B., Houghton P.J., Houghton J.A., Keir S., Marcelli S.L., Bigner D.D., Friedman H.S. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10- (4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. 393:1997;187-191.
29. deSouza P.L., Cooper M.R., Imondi A.R., Myers C.E. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. Clin. Cancer Res. 3:1997;287-294.
30. Zamboni W.C., Stewart C.F., Thompson J., Santana V., Cheshire P.J., Richmond L.B., Liu X., Houghton J.A., Houghton P.J. The relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl. Cancer Inst. 90:1998;505-511.
31. Giovanella B.C., Natelson E., Harris N., Vardeman D., Stehlin J.S. Protocols for the treatment of human tumor xenografts with camptothecins. Ann. NY Acad. Sci. 803:1996;181-187.
32. D'Arpa P., Beardmore C., Lui L.F. Involvement of nucleic acid synthesis in killing mechanisms of topoisomerase poisons. Cancer Res. 50:1990;6919-6924.
33. Kaufmann S.H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 51:1991;1129-1136.
34. Bertrand R., O'Connor P.M., Kerrigan D., Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer. 28A:1992;743-748.
35. Kim R., Hirabayashi N., Nishiyama M., Jinushi K., Toge T., Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer. 50:1992;760-766.
36. Houghton J.A., Cheshire P.J., Hallman J.D., Lutz L., Luo X., Li Y., Houghton P.J. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin. Cancer Res. 2:1996;107-118.
37. Miki T., Kotake T. Advantages in combination chemotherapy using the camptothecin analogue CPT-11 and cisplatinum analogues for human testicular cancer xenografts. Hinyokika Kiyo (Acta Urol. Jpn.). 39:1993;1221-1225.
38. Boscia R.E., Korbut T., Holden S.A., Ara G., Teicher B. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int. J. Cancer. 53:1993;118-123.
39. Kirichenko A.V., Rich T.A., Newman R.A., Travis E.L. Potentiation of murine Mca-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Cancer Res. 57:1997;1929-1933.
40. Houghton P.J., Stewart C.F., Zamboni W.C., Thompson J., Luo X., Danks M.K., Houghton J.A. Schedule-dependent efficacy of camptothecins in models of human cancer. Ann. NY Acad. Sci. 803:1996;188-201.
41. Erickson-Miller C.L., May R.D., Tomaszewski J., Osborn B., Murphy M.J., Page J.C., Parchment R.E. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother. Pharmacol. 39:1997;467-472.
42. Wiseman L.R., Markham A. Irinotecan. Drugs. 52:1996;606-623.
43. Ikuno N., Soda H., Watanabe M., Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J. Natl. Cancer Inst. 87:1995;1876-1883.
44. - secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 351:1995;309-314.
45. Takasuna K., Hagiwara T., Hirohashi M., Kato M., Nomura M., Nagai E., Yokoi T., Kamataki T. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11). Cancer Res. 56:1996;3752-3757.
46. J.A. Bacon, D.K. Petrella, C.T. Cramer, Y. Maruyama, C. Ford, D. Stapert, R.G. Ulrich, Intestinal toxicity and changes in proliferating cell nuclear antigen (PCNA) levels in hamsters induced by a camptothecin analogue, Toxicologist (1996) (abstr.).
47. Stewart C.F., Zamboni W.C., Crom W.R., Houghton P.J. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother. Pharmacol. 40:1997;259-265.
48. Abigerges D., Chabot G.G., Armand J., Herait P., Gouyette A., Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every three weeks in cancer patients. J. Clin. Oncol. 13:1995;210-221.
49. Catimel G., Chabot G.G., Guastalla J.P., Dumortier A., Cote C., Engel C., Gouyette A., Mathieu-Boue A., Mahjoubi M., Clavel M. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann. Oncol. 6:(2):1995;133-140.
50. Rothenberg M.L., Kuhn J.G., Burris H.A., et al. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11:1993;2194-2204.
51. Burke T.G., Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem. 37:1994;40-46.
52. Burke T.G., Munshi C.B., Mi Z., Jiang Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs (letter) (published erratum appears). J. Pharm. Sci. 84:1995;518-519.
53. Liehr J.G., Ahmed A.E., Giovanella B.C. Pharmacokinetics of camptothecins administered orally. Ann. NY Acad. Sci. 803:1996;157-163.
54. Daud S.S., Fetouh M.I., Giovanella B.C. Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anti-Cancer Drugs. 6:1995;83-93.
55. Burke T.G., Gao X. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J. Pharm. Sci. 83:1994;967-969.